Human papillomavirus evaluation of vemurafenib-induced skin epithelial tumors: A case series

British Journal of Dermatology

Volumn 172, Issue 2, 2015, Pages 540-542

  Dika, E ^a   Patrizi, A ^a   Venturoli, S ^b   Fanti, P A ^a   Barbieri, D ^b   Strammiello, R ^b   Melotti, B ^a   La Placa, M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; VEMURAFENIB; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

ALPHAPAPILLOMAVIRUS; B RAF KINASE INHIBITOR ASSOCIATED VERRUCOUS KETATOSIS; DRUG INDUCED CANCER; EPITHELIUM CELL; EPITHELIUM TUMOR; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 40; HUMAN PAPILLOMAVIRUS TYPE 43; HUMAN PAPILLOMAVIRUS TYPE 44; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 54; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN PAPILLOMAVIRUS TYPE 69; HUMAN PAPILLOMAVIRUS TYPE 70; HUMAN PAPILLOMAVIRUS TYPE 71; HUMAN PAPILLOMAVIRUS TYPE 74; HYPERKERATOSIS; KERATOACANTHOMA; KERATOSIS; LETTER; METASTATIC MELANOMA; PAPILLOMAVIRUS INFECTION; PARAKERATOSIS; PATHOGENESIS; PRIORITY JOURNAL; ADULT; AGED; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; FEMALE; GENETICS; MALE; MIDDLE AGED; PAPILLOMAVIRIDAE; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; GENOTYPE; HUMANS; INDOLES; MALE; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84922908111     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13275     Document Type: Letter

References (10)

1. Anforth R, Fernandez-Penas P, Long GV,. Cutaneous toxicities of RAF inhibitors. Lancet Oncol 2013; 14: 11-18.
2. Lacouture M, Duvic M, Hauschild A, et al,. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 2013; 18: 314-22.
3. Su F, Viros A, Milagre C, et al,. RAS mutations in cutaneous squamous cell carcinoma in patients treated with BRAF inhibitors. N Engl J Med 2012; 366: 207-15.
4. Anforth R, Tembe V, Blumetti T, et al,. Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors. Pigment Cell Melanoma Res 2012; 25: 569-72.
5. Ganzenmueller T, Hage E, Yakushko Y, et al,. No human virus sequences detected by next generation sequencing in benign verrucous skin tumors occurring in BRAF inhibitor treated patients. Exp Dermatol 2013; 22: 725-9.
6. Ko CJ, McNiff JM, Iftner A, et al,. Vemurafenib (PLX-4032)-induced keratoses: verrucous but not verrucae. J Am Acad Dermatol 2013; 69: e95-6.
7. IARC. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 2007: 901-36.
8. Schiffman M, Clifford G, Buonaguro FM,. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009; 4: 8.
9. Antonsson A, Forslund O, Ekberg H, et al,. The ubiquity and impressive genomic diversity of human skin papillomaviruses suggest a commensalic nature of these viruses. J Virol 2000; 74: 11636-41.
10. Falchook GS, Rady P, Hymes S, et al,. Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib. JAMA Dermatol 2013; 149: 322-6.